People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capstan Therapeutics, Inc. | — | Biotechnology | Series C | $227.0M | $881.9M | 2021 |
| ImmPACT Bio USA Inc. | — | Biotechnology | Series D+ | $143.6M | $3.5B | 2020 |
| Adicet Bio, Inc. | — | Biotechnology | Series C | $116.8M | $3.3B | 2019 |
| ONL Therapeutics, Inc. | — | Biotechnology | Series C | $111.5M | $495.5M | 2024 |
| FORE US Bio Inc. | — | Biotechnology | Series C | $99.5M | $243.2M | 2023 |
| Averna Therapeutics Inc. | — | Pharma | Series C | $85.0M | $805.0M | 2024 |
| Redona Therapeutics, Inc. | — | Biotechnology | Series C | $66.8M | $76.1M | 2018 |
Michal Silverberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michal Silverberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Erez Chimovits | 4 | 7 |
| Asish Xavier | 2 | 18 |
| Marian Nakada | 2 | 4 |
| Carl Gordon | 1 | 24 |
| Luke Evnin | 1 | 12 |
| Jonathan Silverstein | 1 | 10 |
| Briggs Morrison | 1 | 8 |
| Dylan Morris | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Henry Chen | 1 | 7 |
| Laura Shawver | 1 | 6 |
| Aaron Fletcher | 1 | 5 |
| Yair Schindel | 1 | 4 |
| Donald Santel | 1 | 4 |
| Kazumi Shiosaki | 1 | 4 |
| Michael Baran | 1 | 4 |
| Dieter Weinand | 1 | 4 |
| Florent Gros | 1 | 4 |
| Richard Morris | 1 | 4 |
| Nandita Shangari | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.